Oryzon Genomics S.A./€ORY
1D1W1MYTD1Y5YMAX
Capital at risk
About Oryzon Genomics S.A.
Oryzon Genomics S.A. is a Spanish biotechnology company focused on developing innovative therapies through the discovery and development of epigenetic therapeutics. Founded in 2000 and headquartered in Madrid, Spain, Oryzon's research concentrates on LSD1 inhibitors, primarily for oncology and neurodegenerative diseases. The company's leading compounds include iadademstat for cancer treatment and vafidemstat for neurological conditions. Oryzon's unique position in the epigenetics field is supported by its extensive intellectual property portfolio and strategic partnerships with leading pharmaceutical entities. The company operates within the broader pharmaceutical and biotechnology industry, with a specific focus on drug discovery and development.
- Ticker
- €ORY
- Sector
- Health
- Primary listing
- BME
- Employees
- 46
- Headquarters
- Cornellà de Llobregat, Spain
- Website
- www.oryzon.com/en
ORY Metrics
BasicAdvanced
€230M
-
-€0.03
0.44
-
Price and volume
Market cap
€230M
Beta
0.44
52-week high
€3.88
52-week low
€2.65
Average daily volume
134K
Financial strength
Current ratio
1.596
Quick ratio
1.588
Long term debt to equity
0.041
Total debt to equity
0.09
Profitability
EBITDA (TTM)
-5.841
Gross margin (TTM)
97.75%
Net profit margin (TTM)
-15.76%
Operating margin (TTM)
-38.56%
Effective tax rate (TTM)
59.35%
Revenue per employee (TTM)
€330,000
Management effectiveness
Return on assets (TTM)
-2.66%
Return on equity (TTM)
-2.08%
Valuation
Price to revenue (TTM)
14.113
Price to book
1.82
Price to tangible book (TTM)
1.82
Price to free cash flow (TTM)
-11.106
Free cash flow yield (TTM)
-9.00%
Free cash flow per share (TTM)
-0.253
Growth
Revenue change (TTM)
106.23%
Earnings per share change (TTM)
-40.52%
3-year revenue growth (CAGR)
-1.23%
10-year revenue growth (CAGR)
11.82%
3-year earnings per share growth (CAGR)
-19.82%
10-year earnings per share growth (CAGR)
-13.68%
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.